Page 822 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

800 PART IV Specific Malignancies in the Small Animal Patient

79. Stafford Johnson M, Martin M, Binns S, et al.: A retrospective 99. Ogilvie GK, Powers BE, Mallinckrodt CH, et al.: Surgery and
study of clinical findings, treatment, and outcome in 143 dogs with doxorubicin in dogs with hemangiosarcoma, J Vet Intern Med
pericardial effusion, J Small Anim Pract 45:546–552, 2004. 10:379–384, 1996.
VetBooks.ir 80. MacDonald KA, Cagney O, Magne ML: Echocardiographic and 100. Sorenmo KU, Baez JL, Clifford CA, et al.: Efficacy and toxicity of a
clinicopathologic characterization of pericardial effusion in dogs:
dose-intensified doxorubicin protocol in canine hemangiosarcoma,
107 cases (1995-2006), J Am Vet Med Assoc 235:1456–1461,
J Vet Intern Med 18:209–213, 2004.
2009. 101. Sorenmo KU, Jeglum KA, Helfand SC: Chemotherapy of canine
81. Ratterree W, Gieger T, Pariaut R, et al.: Value of echocardiography hemangiosarcoma with doxorubicin and cyclophosphamide, J Vet
and electrocardiography as screening tools prior to doxorubicin Intern Med 7:370–376, 1993.
administration, J Am Anim Hosp Assoc 48:89–96, 2012. 102. Sorenmo K, Duda L, Barber L, et al.: Canine hemangiosarcoma
82. Wendelburg KM, O’Toole TE, McCobb E, et al.: Risk factors for treated with standard chemotherapy and minocycline, J Vet Intern
perioperative death in dogs undergoing splenectomy for splenic Med 14:395–398, 2000.
masses: 539 cases (2001-2012), J Am Vet Med Assoc 245:1382– 103. Hammer AS, Couto CG, Filppi J, et al.: Efficacy and toxicity of VAC
1390, 2014. chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in
83. LeBlanc AK, Daniel GB: Advanced imaging for veterinary cancer dogs with hemangiosarcoma, J Vet Intern Med 5:160–166, 1991.
patients, Vet Clin Small Anim 37:1059–1077, 2007. 104. Dervisis NG, Dominguez PA, Newman RG, et al.: Treatment with
84. Clifford CA, Pretorius ES, Weisse C, et al.: Magnetic resonance DAV for advanced-stage hemangiosarcoma in dogs, J Am Anim
imaging of focal splenic and hepatic lesions in the dog, J Vet Intern Hosp Assoc 46:170–178, 2011.
Med 18:330–338, 2004. 105. Payne SE, Rassnick KM, Northrup NC, et al.: Treatment of vascu-
85. Fife WD, Samii VF, Drost WT, et al.: Comparison between lar and soft-tissue sarcomas in dogs using an alternating protocol of
malignant and nonmalignant splenic masses in dogs using con- ifosfamide and doxorubicin, Vet Comp Oncol 1:171–179, 2003.
trast-enhanced computed tomography, Vet Radiol Ultrasound 106. Finotello R, Stefanello D, Zini E, et al.: Comparison of doxoru-
45:289–297, 2004. bicin-cyclophosphamide with doxorubicin-dacarbazine for the
86. Armbrust LJ, Biller DS, Bamford A, et al.: Comparison of three- adjuvant treatment of canine hemangiosarcoma, Vet Comp Oncol
view thoracic radiography and computed tomography for detection 15:25–35, 2017.
of pulmonary nodules in dogs with neoplasia, J Am Vet Med Assoc 107. Kahn SA, Mullin CM, de Lorimier LP, et al.: Doxorubicin and
240:1088–1094, 2012. deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a
87. Shaw SP, Rozanski EA, Rush JE: Cardiac troponins I and T in dogs pilot study, Can Vet J 54:237–242, 2013.
with pericardial effusion, J Vet Intern Med 18:322–324, 2004. 108. Rassnick KM, Frimberger AE, Wood CA, et al.: Evaluation of ifos-
88. Chun R, Kellihan HB, Henik RA, et al.: Comparison of plasma cardiac famide for treatment of various canine neoplasms, J Vet Intern Med
troponin I concentrations among dogs with cardiac hemangiosarcoma, 14:271–276, 2000.
noncardiac hemangiosarcoma, other neoplasms, and pericardial effusion 109. Teske E, Rutteman GR, Kirpenstein J, et al.: A randomized con-
of nonhemangiosarcoma origin, J Am Vet Med Assoc 237:806–811, trolled study into the efficacy and toxicity of pegylated liposome
2010. encapsulated doxorubicin as an adjuvant therapy in dogs with
89. Duda LE, Sorenmo KU: Urine basic fibroblast growth factor in splenic haemangiosarcoma, Vet Comp Oncol 9:283–289, 2011.
canine hemangiosarcoma. In Proceedings of the Veterinary Cancer 110. Sorenmo K, Samluk M, Clifford C, et al.: Clinical and pharmaco-
Society Annual Conference, 73, 1997, Chicago. kinetic characteristics of intracavitary administration of pegylated
90. Thamm DH, Kamstock DA, Sharp CR, et al.: Elevated serum liposomal encapsulated doxorubicin in dogs with splenic heman-
thymidine kinase activity in canine splenic hemangiosarcoma, Vet giosarcoma, J Vet Intern Med 21:1347–1354, 2007.
Comp Oncol 10:292–302, 2012. 111. Kim SE, Liptak JM, Gall TT, et al.: Epirubicin in the adjuvant
91. Kirby GM, Mackay A, Grant A, et al.: Concentration of lipocalin treatment of splenic hemangiosarcoma in dogs: 59 cases (1997-
region of collagen XXVII alpha I in the serum of dogs with heman- 2004), J Am Vet Med Assoc 231:1550–1557, 2007.
giosarcoma, J Vet Intern Med 25:497–503, 2011. 112. Biller B: Metronomic chemotherapy in veterinary patients with
92. Bertazzolo W, Dell’Orco M, Bonfanti U, et al.: Canine angiosar- cancer: rethinking the targets and strategies of chemotherapy, Vet
coma: cytologic, histologic, and immunohistochemical correla- Clin North Am Small Anim Pract 44:17–829, 2014.
tions, Vet Clin Pathol 34:28–34, 2005. 113. Lana S, U’Ren L, Plaza S, et al.: Continuous low-dose oral chemo-
93. Clendaniel DC, Sivacolundhu RK, Sorenmo KU, et al.: Asso- therapy for adjuvant therapy of splenic hemangiosarcoma in dogs,
ciation between macroscopic appearance of liver lesions and liver J Vet Intern Med 21:764–769, 2007.
histology in dogs with splenic hemangiosarcoma: 70 cases (2004- 114. Finotello R, Henriques J, Sabattini S, et al.: A retrospective analy-
2009), J Am Anim Hosp 50:e6–e10, 2014. sis of chemotherapy switch suggests improved outcome in surgi-
94. Weisse C, Soares N, Beal MW, et al.: Survival times in dogs with cally removed, biologically aggressive canine hemangiosarcoma, Vet
right atrial hemangiosarcoma treated by means of surgical resection Comp Oncol 15:493–503, 2017.
with or without adjuvant chemotherapy: 23 cases (1986-2000), 115. Matsuyama A, Poirier VJ, Mantovani F, et al.: Adjuvant doxoru-
J Am Vet Med Assoc 226:575–579, 2005. bicin with or without metronomic cyclophosphamide for canine
95. Ployart S, Libermann S, Doran I, et al.: Thoracoscopic resection of splenic hemangiosarcoma, J Am Anim Hosp Assoc 53:304–312,
right auricular masses in dogs: 9 cases (2003–2011), J Am Vet Med 2017.
Assoc 242:237–241, 2013. 116. Bray, et al.: Thalidomide prolongs survival in dogs with splenic
96. Morges M, Worley DR, Withrow SJ, et al.: Pericardial free patch hemangiosarcoma, J Small Anim Pract 59:85–91, 2017.
grafting as a rescue technique in surgical management of right atrial 117. Tripp CD, Fidel J, Anderson CL, et al.: Tolerability of metronomic
HSA, J Am Anim Hosp Assoc 47:224–228, 2011. administration of lomustine in dogs with cancer, J Vet Intern Med
97. Verbeke F, Binst D, Stegen L: Total venous inflow occlusion and 25:278–284, 2011.
pericardial auto-graft reconstruction for right atrial hemangiosar- 118. Leach TN, Childress MO, Greene SN, et al.: Prospective trial of
coma resection in a dog, Can Vet J 53:1114–1118, 2012. metronomic chlorambucil chemotherapy in dogs with naturally
98. Case BL, Maxwell M, Aman A, et al.: Outcome evaluation of a occurring cancer, Vet Comp Oncol 10:102–112, 2011.
thoracoscopic pericardial window procedure or subtotal pericardec- 119. Kisseberth WC, Vail DM, Yaissle J, et al.: Phase I clinical evalua-
tomy via thoracotomy for the treatment of pericardial effusion in tion of carboplatin in tumor-bearing cats: a Veterinary Cooperative
dogs, J Am Vet Med Assoc 242:493–498, 2013. Oncology Group study, J Vet Intern Med 22:83–88, 2008.